SERA PROGNOSTICS, INC. [SERA] Filings

10-Q 1 sera-20240630.htm 10-Q sera-20240630

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

___________________________

FORM 10-Q

___________________________

(Mark One)


x			QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2024


☐			TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number: 001-40606

___________________________

SERA PROGNOSTICS, INC.

(Exact Name of Registrant as Specified in its Charter)

___________________________


Delaware						26-1911522
(State or other jurisdiction of incorporation or organization)						(I.R.S. Employer Identification No.)
2749 East Parleys Way, Suite 200 Salt Lake City, Utah						84109
(Address of principal executive offices)						(Zip Code)

Registrant’s telephone number, including area code: (801) 990-0520

___________________________

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Class A Common Stock, $0.0001 par value per share

SERA

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer	o	Accelerated filer	o
Non-accelerated filer	x	Smaller reporting company	x
		Emerging growth company	x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

As of August 2, 2024, the registrant had 32,400,832 and 967,759 shares of Class A and Class B common stock, $0.0001 par value per share, outstanding, respectively.

TABLE OF CONTENTS


		Page
	Special Note Regarding Forward-Looking Statements	3

PART I — FINANCIAL INFORMATION		4
Item 1.	Financial Statements (Unaudited)	4
	Condensed Balance Sheets	4
	Condensed Statements of Operations and Comprehensive Loss	5
	Condensed Statements of Stockholders’ Equity	6
	Condensed Statements of Cash Flows	7
	Notes to Condensed Financial Statements	8
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	21
Item 3.	Quantitative and Qualitative Disclosure About Market Risk	30
Item 4.	Controls and Procedures	31

PART II – OTHER INFORMATION		32
Item 1.	Legal Proceedings	32
Item 1A.	Risk Factors	32
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	74
Item 5.	Other Information	74
Item 6.	Exhibits	77

	Signatures	78

“Sera,” “PreTRM,” “The Pregnancy Company” and our logo are our trademarks. All other service marks, trademarks, and trade names appearing in this quarterly report on Form 10-Q are the property of their respective owners. We do not intend our use or display of other companies’ trade names, trademarks, or service marks to imply a relationship with, or endorsement or sponsorship of us by, these other companies. Solely for convenience, trademarks and tradenames referred to in this quarterly report on Form 10-Q may appear without the ® or ™ symbols, but such references are not intended to indicate in any way that we will not assert, to the fullest extent under applicable law, our rights, or that the applicable owner will not assert its rights, to these trademarks and tradenames. Unless the context otherwise requires, we use the terms “Sera,” “Company,” “we,” “us” and “our” in this report to refer to Sera Prognostics, Inc.

Table of Contents

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This discussion contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. In some cases, you can identify forward-looking statements by words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will,” “would,” or the negative of these words or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:

•estimates of our addressable market, market growth, future revenue, key performance indicators, expenses, capital requirements, and our needs for additional financing;

•our expectations regarding the rate and degree of market acceptance of our products and services, including our PreTRM test;

•the impact of our PreTRM test, including the results of any studies of the test, on the field of bioinformatics and proteomics and the size and growth of the addressable bioinformatics and proteomics market;

•our ability to obtain funding for our operations;

•our ability to manage and grow our business and commercialize our PreTRM test;

•our ability to develop and commercialize new products and services;

•our ability to retain the continued service of our key professionals and to identify, hire, and retain additional qualified professionals;

•the pricing and reimbursement of our products and services;

•the implementation of our business model, strategic plans for our business, products, services, and technology;

•the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology;

•developments relating to our competitors and our industry;

•the accuracy of our estimates regarding expenses, capital requirements, and needs for additional financing;

•the expected impact of global business, political, and macroeconomic conditions, including inflation, increasing interest rates, and volatile market conditions, uncertainty with respect to the federal budget and debt ceiling and potential government shutdowns related thereto, cybersecurity events, instability in the global banking system, and global events, including regional conflicts around the world, on our business, clinical trials, financial condition, liquidity, and results of operations; and

•our financial performance.

These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including those described in the “Risk Factors” section and elsewhere in this report. Moreover, we operate in a very competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties, and assumptions, the forward-looking events and circumstances discussed in this report may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.

You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable as of the date of this report, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this report to conform these statements to new information, actual results or to changes in our expectations, except as required by law.

Table of Contents

PART I — FINANCIAL INFORMATION

Item 1. Financial Statements (Unaudited)

SERA PROGNOSTICS, INC.

Condensed Balance Sheets

(unaudited)

(in thousands, except share and per share data)


	June 30, 2024		December 31, 2023
Assets
Current assets:
Cash and cash equivalents	$	4,664	$	3,880
Marketable securities	46,276		45,199
Accounts receivable	101		160
Other receivables	—		11,310
Prepaid expenses and other current assets	502		795
Total current assets	51,543		61,344
Property and equipment, net	1,607		1,999
Long-term marketable securities	30,006		30,841
Other assets	1,705		1,257
Total assets	$	84,861	$	95,441
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable	$	952	$	1,046
Accrued and other current liabilities	3,181		2,722
Finance lease obligation, current portion	396		440
Deferred revenue	20,228		20,235
Total current liabilities	24,757		24,443
Finance lease obligation, net of current portion	23		196
Operating lease obligation, net of current portion	328		644
Total liabilities	25,108		25,283
Commitments and contingencies (Note 13)
Stockholders' equity:
Common stock, $0.0001 par value; 150,000,000 Class A shares authorized; 32,386,088 and 30,736,513 Class A shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively; 1,500,000 Class B shares authorized; 1,405,259 Class B shares issued as of June 30, 2024 and December 31, 2023; 967,759 Class B shares outstanding as of June 30, 2024 and December 31, 2023.	3		3
Additional paid-in capital	323,257		317,066
Accumulated other comprehensive loss	(211)		(15)
Accumulated deficit	(263,296)		(246,896)
Total stockholders' equity	59,753		70,158
Total liabilities and stockholders' equity	$	84,861	$	95,441

The accompanying notes are an integral part of the condensed financial statements

Table of Contents

SERA PROGNOSTICS, INC.

Condensed Statements of Operations and Comprehensive Loss

(unaudited)

(in thousands, except share and per share data)


	Three Months Ended June 30,				Six Months Ended June 30,
	2024		2023		2024		2023
Revenue	$	24	$	123	$	24	$	223
Operating expenses:
Cost of revenue	20		80		37		142
Research and development	4,406		3,688		8,089		7,791
Selling and marketing	1,099		2,872		2,326		5,690
General and administrative	3,752		4,943		7,922		9,389
Total operating expenses	9,277		11,583		18,374		23,012
Loss from operations	(9,253)		(11,460)		(18,350)		(22,789)
Interest expense	(8)		(14)		(17)		(30)
Other income, net	958		932		1,967		1,712
Net loss	$	(8,303)	$	(10,542)	$	(16,400)	$	(21,107)
Net loss per share, basic and diluted	$	(0.25)	$	(0.34)	$	(0.50)	$	(0.68)
Weighted-average shares outstanding, basic and diluted	32,932,903		31,077,420		32,576,470		31,048,526
Other comprehensive (loss) income:
Unrealized (loss) gain on available-for-sale debt securities, net of tax	$	(30)	$	(215)	$	(196)	$	309
Total other comprehensive (loss) income	(30)		(215)		(196)		309
Comprehensive loss	$	(8,333)	$	(10,757)	$	(16,596)	$	(20,798)

The accompanying notes are an integral part of the condensed financial statements

Table of Contents

SERA PROGNOSTICS, INC.

Condensed Statements of Stockholders’ Equity

(unaudited)

(in thousands, except share data)


	Common Stock (Class A and B)			Additional Paid-In Capital		Accumulated Other Comprehensive Loss		Accumulated Deficit		Total Stockholders' Equity
	Shares	Amount
Balance as of December 31, 2023	31,704,272	$	3	$	317,066	$	(15)	$	(246,896)	$	70,158
Issuance of common stock upon exercise of stock options	425,749	—		1,162		—		—		1,162
Issuance of restricted stock units	431,152	—		—		—		—		—
Common stock warrant exercises	6,168	—		—		—		—		—
Stock-based compensation expense	—	—		1,693		—		—		1,693
Other comprehensive loss	—	—		—		(166)		—		(166)
Net loss	—	—		—		—		(8,097)		(8,097)
Balance as of March 31, 2024	32,567,341	3		319,921		(181)		(254,993)		64,750
Issuance of common stock upon exercise of stock options	464,305	—		1,258		—		—		1,258
Issuance of restricted stock units	287,729	—		—		—		—		—
Issuance of common stock under employee stock purchase plan	32,669	—		55		—		—		55
Common stock warrant exercises	1,803	—		—		—		—		—
Stock-based compensation expense	—	—		2,023		—		—		2,023
Other comprehensive loss	—	—		—		(30)		—		(30)
Net loss	—	—		—		—		(8,303)		(8,303)
Balance as of June 30, 2024	33,353,847	$	3	$	323,257	$	(211)	$	(263,296)	$	59,753


	Common Stock (Class A and B)			Additional Paid-In Capital		Accumulated Other Comprehensive Loss		Accumulated Deficit		Total Stockholders' Equity
	Shares	Amount
Balance as of December 31, 2022	31,017,946	$	3	$	310,575	$	(981)	$	(210,654)	$	98,943
Issuance of common stock upon exercise of stock options	4,094	—		4		—		—		4
Stock-based compensation expense	—	—		1,304		—		—		1,304
Other comprehensive income	—	—		—		524		—		524
Net loss	—	—		—		—		(10,565)		(10,565)
Balance as of March 31, 2023	31,022,040	3		311,883		(457)		(221,219)		90,210
Issuance of common stock upon exercise of stock options	117,839	—		178		—		—		178
Issuance of common stock under employee stock purchase plan	58,626	—		66		—		—		66
Stock-based compensation expense	—	—		1,440		—		—		1,440
Other comprehensive loss	—	—		—		(215)		—		(215)
Net loss	—	—		—		—		(10,542)		(10,542)
Balance as of June 30, 2023	31,198,505	$	3	$	313,567	$	(672)	$	(231,761)	$	81,137

The accompanying notes are an integral part of the condensed financial statements

Table of Contents

SERA PROGNOSTICS, INC.

Condensed Statements of Cash Flows

(unaudited)

(in thousands)


	Six Months Ended June 30,
	2024		2023
Cash flows from operating activities
Net loss	$	(16,400)	$	(21,107)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	421		472
Stock-based compensation	3,716		2,744
Non-cash lease expense	278		259
Non-cash investment income, net	(632)		(426)
Other	16		12
Changes in operating assets and liabilities:
Accounts receivable	59		(50)
Other receivables	11,310		6,000
Prepaid expenses and other assets	203		872
Accounts payable	(42)		(289)
Accrued and other current liabilities	144		(1,284)
Deferred revenue	(7)		(32)
Net cash used in operating activities	(934)		(12,829)
Cash flows from investing activities
Purchases of marketable securities	(26,556)		(23,068)
Proceeds from maturities and sales of marketable securities	26,735		38,113
Purchases of property and equipment	(22)		(86)
Proceeds from disposal of property and equipment	—		269
Purchase of intangible assets	(697)		—
Net cash (used in) provided by investing activities	(540)		15,228
Cash flows from financing activities
Proceeds from exercise of stock options	2,420		182
Proceeds from employee stock purchase plan	55		66
Finance lease principal payments	(217)		(240)
Net cash provided by financing activities	2,258		8
Net increase in cash and cash equivalents	784		2,407
Cash and cash equivalents at beginning of period	3,880		29,878
Cash and cash equivalents at end of period	$	4,664	$	32,285
Supplemental disclosure of cash flow information
Cash paid for interest	$	17	$	30
Supplemental disclosure of non-cash investing and financing information
Purchases of property and equipment in accounts payable and accrued and other current liabilities	$	8	$	—

The accompanying notes are an integral part of the condensed financial statements

Table of Contents

SERA PROGNOSTICS, INC.

Notes to Condensed Financial Statements

(Unaudited)

1. Description of Business and Financial Condition

Sera Prognostics, Inc. (the “Company”) is a women’s health company utilizing its proprietary proteomics and bioinformatics platform, and significant data resources, to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests and predictive analytic products and services. The Company was incorporated in the State of Delaware on January 17, 2008 and its operations are located in Salt Lake City, Utah, including a Clinical Laboratory Improvement Amendments (“CLIA”)-certified laboratory.

Since its inception, the Company’s activities have consisted of performing research and development and conducting clinical studies for its pipeline products and services, acquiring product rights, raising capital, establishing facilities, and organizing commercial operations to market its testing and analytics products, primarily the PreTRM test.

Liquidity and Capital Resources

The accompanying condensed financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business.

The Company has incurred net losses and negative cash flows from operations since inception and had an accumulated deficit of $263.3 million as of June 30, 2024. The Company’s management expects the Company to incur significant additional operating losses and negative cash flows for the foreseeable future, principally as a result of the Company’s activities relating to the PreTRM test and the Company’s other pipeline products and services, including clinical and preclinical trials and anticipated research and development activities as well as commercialization activities. There can be no assurance that the Company will eventually achieve significant revenues or profitability to sustain operations, or if achieved, can sustain either on a continuing basis. If the Company is unable to achieve significant revenues or raise additional funds, when needed, it may not be able to continue the development or commercialization of its products and services and could be required to delay, scale back, or abandon some or all of its operations. No assurance can be given that the Company will be successful in raising the required capital on reasonable terms and at the required times, or at all. Any additional equity financing, if available to the Company, may not be available on favorable terms and may be dilutive to current stockholders, and any debt financing, if available, may involve restrictive covenants and dilutive financing instruments. The Company’s future operations are highly dependent on a combination of factors, including (i) the commercialization and market acceptance of the PreTRM test and the successful development, commercial launch, marketing, and distribution of other pipeline products and services; (ii) the success of scientific and clinical studies and other research and development programs that support current and future products and services; (iii) the development of competitive products by other biotechnology and laboratory companies; (iv) the Company’s ability to manage growth of the organization; (v) the Company’s ability to protect its intellectual property, technology, products and services; and, ultimately (vi) the timely and successful completion of any additional financing.

The principal sources of the Company’s working capital to date have been the proceeds from the sale and issuance of convertible preferred stock and convertible notes, bank loans, and the sale and issuance of Class A common stock in an initial public offering (“IPO”), which was completed in July 2021. As of June 30, 2024, the Company had aggregate cash, cash equivalents, and available-for-sale securities of $80.9 million. See Note 3—Cash, Cash Equivalents and Marketable Securities.

The Company believes that its existing financial resources are sufficient to continue operating activities at least 12 months from the issuance date of these unaudited condensed financial statements.

2. Significant Accounting Policies

Basis of Presentation

The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and applicable rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or

Table of Contents

omitted pursuant to such rules and regulations. As such, these unaudited condensed financial statements should be read in conjunction with the audited financial statements and accompanying notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023. The unaudited interim condensed financial statements have been prepared on a basis consistent with the audited annual financial statements as of and for the year ended December 31, 2023, and, in the opinion of the Company’s management, reflect all adjustments, consisting solely of normal recurring adjustments, necessary for the fair presentation of the Company’s financial results. The balance sheet as of December 31, 2023 has been derived from the audited financial statements at that date but does not include all information and footnotes required by U.S. GAAP for complete financial statements. The results of the three and six months ended June 30, 2024 are not necessarily indicative of the results to be expected for the full year ending December 31, 2024, or any other period.

There have been no significant changes in the Company’s significant accounting policies during the six months ended June 30, 2024, as compared with those disclosed in its Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on March 20, 2024.

Any reference in these notes to applicable accounting guidance is meant to refer to the authoritative U.S. GAAP included in the Accounting Standards Codification (“ASC”), and Accounting Standards Updates (“ASU”) issued by the Financial Accounting Standards Board (“FASB”).

Use of Estimates

The preparation of the condensed financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the amounts reported in the condensed financial statements and accompanying notes. The Company evaluates these estimates on an ongoing basis. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. Actual results could differ materially from those estimates.

The Company’s financial statements as of and for the three and six months ended June 30, 2024 reflect the Company’s estimates of the impact of the current macroeconomic environment, including the impact of inflation and higher interest rates. The extent to which these conditions will directly or indirectly impact the Company’s business, results of operations, and financial condition is uncertain. The Company is not aware of any specific event or circumstance that would require an update to its estimates, judgments and assumptions or a revision of the carrying value of the Company’s assets or liabilities as of the date of this filing.

Recently Issued Accounting Pronouncements Not Yet Adopted

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which is intended to improve the transparency of income tax disclosures by requiring consistent categories and greater disaggregation of information in the effective tax rate reconciliation and income taxes paid by jurisdiction. The ASU is effective for public business entities’ annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting this guidance on its financial statements.

In November 2023, the FASB issued ASU No. 2023-07, Improvements to Reportable Segments Disclosures. While ASU 2023-07 requires incremental disclosures, it does not change how an entity identifies its operating segments, aggregates those operating segments, or applies the quantitative thresholds to determine reportable segments. This ASU is effective for all public business entities for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Entities must adopt the changes to the segment reporting guidance on a retrospective basis. The Company is currently evaluating the impact of adopting this guidance on its financial statements. Early adoption is permitted; however, the Company is not early adopting the standard.

Table of Contents

3. Cash, Cash Equivalents and Marketable Securities

The Company has classified its marketable securities as available-for-sale. The Company’s cash, cash equivalents and marketable securities by major security type as of June 30, 2024 and December 31, 2023 were as follows (in thousands):


	June 30, 2024
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
Cash and cash equivalents:
Cash	$	1,761	$	—	$	—	$	1,761
Money market funds	2,903		—		—		2,903

Total cash and cash equivalents	4,664		—		—		4,664
Current marketable securities:
Commercial paper	7,939		—		(9)		7,930
Corporate debt securities	11,823		—		(23)		11,800
U.S. federal agency securities	20,331		—		(78)		20,253
U.S. government securities	6,321		—		(28)		6,293
Total current marketable securities	46,414		—		(138)		46,276
Long-term marketable securities:


Corporate debt securities	26,998		21		(92)		26,927
Municipal debt securities	3,081		—		(2)		3,079
Total long-term marketable securities	30,079		21		(94)		30,006
Total cash, cash equivalents and marketable securities	$	81,157	$	21	$	(232)	$	80,946


	December 31, 2023
	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses		Fair Value
Cash and cash equivalents:
Cash	$	2,608	$	—	$	—	$	2,608
Money market funds	1,272		—		—		1,272

Total cash and cash equivalents	3,880		—		—		3,880
Current marketable securities:
Commercial paper	11,769		6		(2)		11,773
Corporate debt securities	1,155		—		(2)		1,153
U.S. federal agency securities	19,644		—		(102)		19,542
U.S. government securities	12,812		—		(81)		12,731
Total current marketable securities	45,380		6		(187)		45,199
Long-term marketable securities:
U.S. federal agency securities	9,406		27		(17)		9,416
U.S. government securities	4,388		3		(5)		4,386
Corporate debt securities	16,880		159		—		17,039
Total long-term marketable securities	30,674		189		(22)		30,841
Total cash, cash equivalents and marketable securities	$	79,934	$	195	$	(209)	$	79,920

Table of Contents

The following tables summarize the Company’s available-for-sale debt securities and cash equivalents with unrealized losses as of June 30, 2024 and December 31, 2023, aggregated by major security type and the length of time that individual securities have been in a continuous loss position (in thousands):


	June 30, 2024
	Less than 12 months				12 months or greater				Total
	Fair Value		Unrealized Losses		Fair Value		Unrealized Losses		Fair Value		Unrealized Losses
Commercial paper	$	7,930	$	(9)	$	—	$	—	$	7,930	$	(9)
Corporate debt securities	29,129		(111)		1,151		(4)		30,280		(115)
U.S. federal agency securities	4,790		(14)		14,357		(64)		19,147		(78)
U.S. government securities	1,475		(3)		4,818		(25)		6,293		(28)
Municipal debt securities	$	3,079	$	(2)	$	—	$	—	3,079		(2)
Total	$	46,403	$	(139)	$	20,326	$	(93)	$	66,729	$	(232)


	December 31, 2023
	Less than 12 months				12 months or greater				Total
	Fair Value		Unrealized Losses		Fair Value		Unrealized Losses		Fair Value		Unrealized Losses
Commercial paper	$	5,453	$	(2)	$	—	$	—	$	5,453	$	(2)
Corporate debt securities	1,153		(2)		—		—		1,153		(2)
U.S. federal agency securities	15,308		(52)		8,751		(67)		24,059		(119)
U.S. government securities	4,769		(13)		10,895		(73)		15,664		(86)
Total	$	26,683	$	(69)	$	19,646	$	(140)	$	46,329	$	(209)

As of June 30, 2024 and December 31, 2023, the Company had not recorded any allowance for credit losses related to its available-for-sale securities. The Company attributes the declines in the fair value of its available-for-sale securities to normal market and interest rate fluctuations. The declines in fair value are not attributed to declines in credit quality. The Company does not intend to sell investments while they are in an unrealized loss position and does not believe that it is more likely than not that the Company will be required to sell the investments before recovery of their amortized cost basis, which may be maturity. All of the Company’s investments mature in less than three years.

The Company’s marketable securities classified by contractual maturities as of June 30, 2024 were as follows (in thousands):


	Amortized Cost		Fair Value
Due within one year	$	46,414	$	46,276
Due after one year through five years	30,079		30,006
Total	$	76,493	$	76,282

Table of Contents

4. Property and Equipment

The following table presents the components of property and equipment, net, as of June 30, 2024 and December 31, 2023 (in thousands):


	June 30, 2024		December 31, 2023
Laboratory equipment	$	5,742	$	5,734
Computer equipment	1,074		1,054
Leasehold improvements	772		772
Software	1,141		1,141
Furniture and fixtures	320		320
Total property and equipment	9,049		9,021
Less accumulated depreciation and amortization	(7,442)		(7,022)
Property and equipment, net	$	1,607	$	1,999

Depreciation and amortization expense was $0.2 million for each of the three months ended June 30, 2024 and 2023. Depreciation and amortization expense was $0.4 million and $0.5 million for the six months ended June 30, 2024 and 2023, respectively.

5. Other Assets

The following table presents the components of other assets as of June 30, 2024 and December 31, 2023 (in thousands):


	June 30, 2024		December 31, 2023
Operating right-of-use asset	$	902	$	1,180
Intangible assets	697		—
Other assets	106		77
Total other assets	$	1,705	$	1,257

During the six months ended June 30, 2024, the Company acquired domain names resulting in capitalized intangible assets of $697,000. The Company determined that the domain names have an indefinite useful life and are therefore not subject to amortization. The Company assesses its intangible assets for impairment annually, or more frequently if circumstances dictate.

6. Accrued and Other Current Liabilities

The following table presents the components of accrued and other current liabilities as of June 30, 2024 and December 31, 2023 (in thousands):


	June 30, 2024		December 31, 2023
Accrued compensation	$	513	$	779
Accrued vacation	466		365
Accrued 401(k) matching contributions	216		74
Operating lease liability, current portion	610		578
Other current liabilities	1,376		926
Total accrued and other current liabilities	$	3,181	$	2,722

Table of Contents

7. Other Income, net

The following table presents the components of other income, net, for the three and six months ended June 30, 2024 and 2023 (in thousands):


	Three Months Ended June 30,				Six Months Ended June 30,
	2024		2023		2024		2023
Interest income	$	671	$	337	$	1,341	$	593
Investment income, net	287		595		626		1,119
Other income, net	$	958	$	932	$	1,967	$	1,712

8. Fair Value Measurements

As of June 30, 2024 and December 31, 2023, the carrying amounts of the Company’s receivables, prepaid and other current assets, accounts payable, and accrued and other current liabilities approximate their fair values, principally due to the short-term nature of the assets and liabilities. The recorded values of the finance leases approximate fair value as the interest rates approximate market interest rates.

Money market funds are highly liquid investments and are actively traded. The pricing information on money market funds is readily available and can be independently validated as of the measurement date. This approach results in the classification of these securities as Level 1 of the fair value hierarchy.

U.S. government agency bonds, U.S. government bonds, commercial paper, corporate debt securities, and municipal debt securities are measured at fair value using Level 2 inputs. The Company reviews trading activity and pricing for these investments as of each measurement date.

The Company follows a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. The three levels of the fair value hierarchy are as follows:

Level 1 inputs are observable, quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company can access at the measurement date.

Level 2 inputs are observable inputs other than quoted prices included in Level 1 that are observable either directly or indirectly or quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 inputs are unobservable inputs in which there is little or no market data, which require the Company to develop its own assumptions.

Table of Contents

The following table shows the Company’s assets measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands) as of June 30, 2024:


	Level 1		Level 2		Level 3
Assets:
Cash equivalents:
Money market funds	$	2,903	$	—	$	—

Marketable securities:
Commercial paper	—		7,930		—
Corporate debt securities	—		38,727		—
Municipal debt securities	—		3,079		—
U.S. federal agency securities	—		20,253		—
U.S. government securities	—		6,293		—
Total assets	$	2,903	$	76,282	$	—

The following table shows the Company’s assets measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands) as of December 31, 2023:


	Level 1		Level 2		Level 3
Assets:
Cash equivalents:
Money market funds	$	1,272	$	—	$	—

Marketable securities:
Commercial paper	—		11,773		—
Corporate debt securities	—		18,192		—
U.S. federal agency securities	—		28,958		—
U.S. government securities	—		17,117		—
Total assets	$	1,272	$	76,040	$	—

9. Related Party Transactions

In June 2019, the Company entered into a master services agreement with Carelon Research, a subsidiary of Elevance Health, Inc. (“Elevance Health”). This agreement covers a range of research projects, including Carelon Research’s role as a contract research organization for the Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs (“PRIME”) study. The Company paid fees related to this agreement of $0.8 million for each of the three months ended June 30, 2024 and 2023, and $1.4 million and $1.7 million for the six months ended June 30, 2024 and 2023, respectively, which were recorded in research and development expenses in the Company’s condensed statements of operations and comprehensive loss. In November 2020, the Company entered into a Laboratory Services Agreement with Elevance Health related to the PRIME study. This agreement provides a contracted rate for certain tests performed pursuant to the study. In December 2023, enrollment in the PRIME study was stopped due to efficacy, and as such, there was an immaterial amount of revenue recognized related to this agreement for the three and six months ended June 30, 2024. The Company recognized revenue related to this agreement of $14 thousand and $34 thousand for the three and six months ended June 30, 2023.

Table of Contents

In February 2021, the Company entered into a commercial collaboration agreement with Elevance Health and its affiliates (the “Commercial Collaboration Agreement”). The Commercial Collaboration Agreement provides defined payment within a defined period for use of the PreTRM test within Elevance Health’s network of covered members. Pursuant to the Commercial Collaboration Agreement, Elevance Health agreed to purchase a certain minimum number of tests for each of the first three years of the term of the agreement. Additionally, Elevance Health agreed to pay a certain minimum amount per year for the first three years of the term of the Commercial Collaboration Agreement. The Company received $11.2 million during the six months ended June 30, 2024, which amount related to the minimum payments for the year ended December 31, 2023. Such minimum payments were initially recorded as deferred revenue. Deferred revenue is recognized as revenue when the Company delivers PreTRM test results to Elevance Health patients pursuant to the Commercial Collaboration Agreement. The Company also agreed to develop a sales, marketing, and customer service program, and to provide training and marketing to duly licensed physicians specializing in obstetrics and gynecology or family medicine, or licensed nurse midwives, at the reasonable request of Elevance Health.

Elevance Health has been participating in the Company’s PRIME study, and at the conclusion of the PRIME study, under the Commercial Collaboration Agreement, the parties agreed to use commercially reasonable efforts to enter into Elevance Health’s standard lab provider agreement. Unless earlier terminated due to breach, the Commercial Collaboration Agreement will remain in effect until the later of (a) the third anniversary of the effective date or (b) the date on which Elevance Health has purchased a fixed number of PreTRM tests as agreed by the parties.

The Commercial Collaboration Agreement with Elevance Health is considered to be within the scope of ASC Topic 808, Collaborative Arrangements (“ASC 808”), as the parties are active participants and exposed to the risks and rewards of the collaborative activity. The Company determined the PreTRM tests to be a performance obligation for which Elevance Health is a customer and a unit of account within the scope of ASC 606. The associated transaction price is based on the contractual minimum number of tests and the agreed upon defined payment amount per test. The transaction price was allocated to this single performance obligation, which will be recognized upon delivery of test results expected to occur over the term of the agreement. All other items promised to Elevance Health are immaterial in the context of the Commercial Collaboration Agreement. There were no material revenues related to the Commercial Collaboration Agreement for the three and six months ended June 30, 2024 and 2023.

10. Capital Structure

The Company has two authorized classes of common stock, Class A and Class B. The rights of the holders of Class A and Class B common stock are identical, except with respect to voting and conversion. Each share of Class A common stock is entitled to one vote and shares of Class B common stock are non-voting. Each share of Class B common stock may be converted at any time to one share of Class A common stock at the option of its holder, subject to the ownership limitations provided for in the Company’s amended and restated certificate of incorporation.

The following shares of Class A common stock were reserved for future issuance:


	June 30, 2024	December 31, 2023
Warrants to purchase Class A common stock	2,649,720	2,775,978
Options to purchase Class A common stock	6,336,742	7,251,663
Restricted stock units outstanding	2,118,834	2,692,459
Class A common stock available for future grants under the 2021 Equity Incentive Plan	2,111,162	1,002,091
Class A common stock available for future grants under the 2021 Employee Stock Purchase Plan	1,076,364	801,668
Total	14,292,822	14,523,859

11. Stock-Based Compensation

Equity Incentive Plans

In November 2011, the Company established the 2011 Employee, Director and Consultant Equity Incentive Plan (the “2011 Plan”) and reserved shares of the Company’s common stock for sale and issuance under the 2011 Plan. Options granted under the 2011 Plan generally vest over a four-year period and generally expire ten years from the date of grant. Options are exercisable only to the extent vested. The 2011 Plan terminated in November 2021, and accordingly, no

Table of Contents

additional shares are available for grant under the 2011 Plan. The 2011 Plan continues to govern outstanding awards granted under the 2011 Plan.

The 2021 Equity Incentive Plan (the “2021 Plan”) was established in July 2021. The 2021 Plan provides for the grant of incentive and non-statutory stock options as well as other stock rights to employees, directors, and consultants of the Company. Options generally vest over a four-year period, are exercisable only to the extent vested, and generally expire ten years from the date of grant. Restricted stock units (“RSUs”) generally vest over either a two-year or four-year period. The 2021 Plan includes provisions for annual automatic increases to the number of shares of Class A common stock reserved for issuance under the 2021 Plan. In addition, any shares that otherwise would be returned to the 2011 Plan as a result of the expiration or cancellation of stock options may be added to the 2021 Plan. As of June 30, 2024, there were 2,111,162 shares of the Company’s Class A common stock that were available for future grants under the 2021 Plan.

The 2021 Employee Stock Purchase Plan (the “2021 ESPP”) was established in July 2021. The 2021 ESPP includes provisions for annual automatic increases to the number of shares of Class A common stock reserved for issuance under the 2021 ESPP. As of June 30, 2024, there were 1,076,364 shares of the Company’s Class A common stock that were available for future grants under the 2021 ESPP.

Stock Options

Unless otherwise noted, references to “options” in the subsequent disclosures, refers to the combined incentive and non-statutory stock options issued as employee and non-employee stock-based compensation, and authorized under the 2011 Plan and the 2021 Plan. The following table summarizes information about these options granted and outstanding:


	Number of Shares Subject to Options Outstanding	Weighted- Average Exercise Price Per Share		Weighted- Average Remaining Contractual Life (In Years)	Aggregate Intrinsic Value (In Thousands)
Outstanding — December 31, 2023	7,251,663	$	3.66	6.9	$	20,014
Granted	73,843	8.43
Expired	—	—
Cancelled	(98,710)	3.62
Exercised	(890,054)	2.72
Outstanding — June 30, 2024	6,336,742	$	3.84	6.7	$	16,497
Vested and expected to vest at June 30, 2024	6,257,911	$	3.83	6.7	$	16,355
Vested and exercisable at June 30, 2024	5,174,134	$	3.54	6.5	$	14,747

RSUs

The following table summarizes information about RSUs granted and outstanding under the 2021 Plan:


	Number of Awards	Weighted-Average Grant Date Fair Value
Outstanding — December 31, 2023	2,692,459	$	2.01
Granted	188,173	9.00
Forfeited	(42,917)	2.05
Vested	(718,881)	2.53
Outstanding — June 30, 2024	2,118,834	$	2.46

Table of Contents

Stock-Based Compensation Expense

The following table presents the impact of stock-based compensation expense in the statements of operations for the periods indicated (in thousands):


	Three Months Ended June 30,				Six Months Ended June 30,
	2024		2023		2024		2023
Research and development expense	$	918	$	382	$	1,444	$	732
Sales and marketing expense	92		294		177		477
General and administrative expense	1,013		764		2,095		1,535
Total employee stock-based compensation	$	2,023	$	1,440	$	3,716	$	2,744

The information about unrecognized stock-based compensation expense for outstanding unvested stock options and RSUs as of June 30, 2024 was as follows (in thousands, except years):


	Unrecognized Stock-Based Compensation Expense		Weighted-Average Period of Recognition (in years)
Stock Options	$	3,550	1.3
RSUs	3,969		2.0
Total unrecognized stock-based compensation expense	$	7,519

12. Warrants

All outstanding common stock warrants were exercisable immediately when granted. All outstanding common stock warrants are exercisable for shares of Class A common stock. The Company’s common stock warrants outstanding were as follows:


		Number of Warrants Outstanding as of:
Exercise Price		June 30, 2024	December 31, 2023
$	5.20	3,473	3,473
9.03		969,275	1,032,404
10.84		946,666	1,009,795
12.38		8,083	8,083
20.77		722,223	722,223
		2,649,720	2,775,978

During the six months ended June 30, 2024, 126,258 common stock warrants were net exercised, resulting in the issuance of 7,971 shares of Class A common stock.

13. Commitments and Contingencies

Leases

The Company is the lessee in all of its lease arrangements. The Company did not enter into any leases with related parties during the presented periods. The Company makes assumptions and judgments when assessing contracts for lease components, determining lease classifications, and calculating right-of-use asset and lease liability values. These assumptions and judgments may include the useful lives and fair values of the leased assets, the implicit rate underlying the Company’s leases, the Company’s incremental borrowing rate or the Company’s intent to exercise or not exercise options available in lease contracts.

Table of Contents

The following table shows right-of-use assets and lease liabilities, and the associated financial statement line items as of June 30, 2024 and December 31, 2023 (in thousands):


Lease-Related Assets and Liabilities	Financial Statement Line Items	June 30, 2024		December 31, 2023
Right-of-use assets:
Operating leases	Other assets	$	902	$	1,180
Finance leases	Property and equipment, net	855		1,008
Total right-of-use assets		$	1,757	$	2,188

Lease liabilities:
Operating leases	Accrued and other current liabilities	$	610	$	578
	Operating lease obligation, net of current portion	328		644
Finance leases	Finance lease obligation, current portion	396		440
	Finance lease obligation, net of current portion	23		196
Total lease liabilities		$	1,357	$	1,858

Lease costs and other information consisted of the following (in thousands, except terms and rates):


	Three Months Ended June 30,				Six Months Ended June 30,
	2024		2023		2024		2023
Lease cost
Finance lease cost:
Amortization of right-of-use assets	$	78	$	83	$	157	$	166
Interest on lease liabilities	8		14		17		30
Operating lease cost	159		159		318		318
Total lease cost	$	245	$	256	$	492	$	514

Other information
Finance leases:
Operating cash outflows	$	8	$	14	$	17	$	30
Financing cash outflows	$	109	$	120	$	217	$	240
Right-of-use assets obtained in exchange for lease liabilities	$	—	$	18	$	—	$	18
Weighted-average remaining lease term (in years)	0.9		1.8		0.9		1.8
Weighted-average discount rate	6.6%		6.5%		6.6%		6.5%
Operating leases:
Operating cash outflows	$	162	$	157	$	323	$	314
Right-of-use assets obtained in exchange for lease liabilities	$	—	$	—	$	—	$	—
Weighted-average remaining lease term (in years)	1.5		2.5		1.5		2.5
Weighted-average discount rate	7.5%		7.5%		7.5%		7.5%

Table of Contents

Future minimum lease payments for the Company’s leases as of June 30, 2024 were as follows (in thousands):


	Operating Leases		Finance Leases		Total
2024	$	323	$	233	$	556
2025	666		197		863
2026	—		2		2
2027 and thereafter	—		—		—

Total minimum lease payments	989		432		1,421
Less: imputed interest	(51)		(13)		(64)
Present value of future lease payments	938		419		1,357
Less: current portion	610		396		1,006
Long-term portion	$	328	$	23	$	351

Operating Leases

The Company leases a total of approximately 24,300 square feet of office and laboratory space under a single non-cancelable operating lease with a termination date of December 31, 2025 (as amended, the “Office Lease”). The Office Lease includes an early termination right which termination would occur under certain circumstances, as provided in the amended Office Lease, after July 1, 2024, if exercised. The Company is not currently reasonably certain it will exercise the termination right. The implicit rate provided in the Company’s operating lease is not readily determinable. As such, the Company uses its incremental borrowing rate to calculate the present value of its operating lease liabilities.

Finance Leases

The Company leases certain equipment related to its information technology infrastructure and laboratory operations. All of the Company’s current finance leases include bargain purchase options that the Company is reasonably certain to exercise. The Company has elected not to separate lease and non-lease components for its equipment leases. The rates implicit in the Company’s finance leases are determinable, and the Company uses those rates to calculate the present value of its finance lease liabilities.

Indemnification

The Company has agreed to indemnify its officers and directors for certain events or occurrences while the officer or director is or was serving at the Company’s request in such capacity. The maximum amount of potential future indemnification is unlimited; however, the Company purchases director and officer insurance coverage that provides for corporate reimbursements of covered obligations that limits the Company’s exposure and enables it to recover a portion of potential future amounts paid. The Company is unable to reasonably estimate the maximum amount that could be payable under these arrangements since these obligations are not capped but are conditional to the unique facts and circumstances involved. Accordingly, the Company has no liabilities recorded for these agreements as of June 30, 2024 and December 31, 2023. The Company has never incurred costs to defend lawsuits or settle claims related to these indemnification agreements.

Employee Agreements

The Company has signed various employment agreements with key executives pursuant to which, if their employment is terminated by the Company without cause or by the employees for good reason, or following a change of control of the Company, the employees are entitled to receive certain benefits, including severance payments, accelerated vesting of stock and stock options, and certain insurance benefits.

Legal Matters

The Company is not currently a party to any material litigation or other material legal proceedings. The Company may, from time to time, be involved in various legal proceedings arising from the normal course of business activities, and an unfavorable resolution of any of these matters could materially affect the Company’s future results of operations, cash flows, or financial position.

Table of Contents

14. Net loss per share

The Company calculates net loss per share of Class A and Class B common stock using the two-class method. For periods in which the Company reports a net loss, all potentially dilutive shares are anti-dilutive and are therefore excluded from the calculation of diluted net loss per share. For the three and six months ended June 30, 2024 and 2023, the Company reported net losses and as such, basic and diluted net loss per share are the same.

As the liquidation and dividend rights are identical for Class A and Class B common stock, the undistributed earnings are allocated on a proportionate basis and the resulting amount per share for Class A and Class B common stock was the same for the three and six months ended June 30, 2024 and 2023.

The Company excluded the following potentially dilutive securities, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated because their impact would have been anti-dilutive:


	June 30,
	2024	2023
Warrants to purchase Class A common stock	2,649,720	2,775,978
Options to purchase Class A common stock	6,336,742	8,062,442
Restricted stock units outstanding	2,118,834	240,832
Total	11,105,296	11,079,252

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q. Some of the information contained in this discussion and analysis or set forth elsewhere in this Form 10-Q, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the “Risk Factors” section of this Form 10-Q, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

Investors and others should note that we routinely use the Investors section of our website to announce material information to investors and the marketplace. While not all of the information that we post on the Investors section of our website is of a material nature, some information could be deemed to be material. Accordingly, we encourage investors, the media, and others interested in us to review the information that we share on the Investors section of our website, investors.seraprognostics.com.

Overview

We are a women’s health company utilizing our proprietary proteomics and bioinformatics platform, and significant data resources, to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests and predictive analytic products and services. Our vision is to deliver pivotal and actionable information to pregnant women, their physicians, and health care payers to significantly enhance a mother’s pregnancy journey, improve maternal and neonatal health, and dramatically reduce health care costs. We believe that our method of combining the disciplines of proteomics and bioinformatics with rigorous clinical testing, data, and economic analysis enables us to provide physicians and expectant mothers with personally insightful, clinically meaningful, and economically impactful information designed to improve the pregnancy experience and outcomes for mothers and babies.

There are approximately 140 million births globally each year, and approximately 3.7 million births annually in the United States. Of these, it is estimated that as many as 30% are affected by various complications (i.e., a high-risk pregnancy), including: preterm birth, preeclampsia, fetal growth restriction, stillbirth, hypertension of pregnancy, gestational diabetes, and others. In many cases these complications have profound short- and long-term health consequences for the mother and baby. These health consequences of preterm birth alone are estimated to be approximately $25 billion annually in the United States. This underscores that existing methods to predict adverse pregnancy outcomes are insufficient for timely and effective proactive management for the vast majority of high-risk pregnancies. We believe that positive patient outcomes are the result of appropriate care, and the primary differentiator of patient care should be based on a determination of risk informed by a number of factors including our novel diagnostic tests.

Our first commercial product, the PreTRM test, is the only broadly validated, commercially available blood-based biomarker test to accurately predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation that provides an accurate prediction of the expectant mother’s risk of delivering spontaneously before 37 weeks’ gestation. Our commercialization strategy includes conducting clinical trials to demonstrate the health and economic benefits of early and accurate detection of preterm birth risk coupled with well-recognized interventions in higher risk patients, illustrating these benefits to healthcare providers and insurance payers, and providing convenient access to the test through streamlined specimen collection options. Beyond demonstration of efficacy, we look forward to studying the effectiveness and implementation of the PreTRM test in a real-world setting. Clinical trials conducted to date include the Prediction and Prevention of Preterm Birth, or the PREVENT-PTB Study, Serum Assessment of Preterm Birth Outcomes Compared to Historical Controls study, or the AVERT PRETERM TRIAL, and the Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs study, or the PRIME study. Manuscript results of these studies demonstrate consistency in the reported beneficial impact of the PreTRM test-and-treat strategy. Specifically, this includes evidence of a prolongation of gestation, shortened hospital or neonatal intensive care unit, or NICU, length of stay, and improvements in measures of neonatal morbidity/mortality. Our studies demonstrate a model indicating that by identifying and intervening in at-risk pregnancies, not identifiable by other approaches, babies destined for premature delivery remain in utero longer. This prolongation of gestation in the preterm period leads to more mature babies that require shorter hospital/NICU stays due to improved neonatal health. The PRIME study, for which enrollment was stopped due to efficacy at the interim analysis and is being prepared for publication, includes the same Primary and Secondary outcomes as the AVERT PRETERM TRIAL and affords the continued assessment of this model.

Table of Contents

We believe market adoption by both health care providers and payers should be aided by the publications of our PREVENT-PTB study sub-analysis and the peer-reviewed positive data from our AVERT PRETERM TRIAL, as well as upcoming publications, including the results of our PRIME study and other real-world evidence studies. We believe the data that will be published in coming years, together with our current body of evidence, will further demonstrate the clinical and economic utility of our test.

In December 2023, we announced that the Data Safety Monitoring Board, or DSMB, overseeing our PRIME study recommended stopping enrollment due to efficacy, reporting that either co-primary endpoints, neonatal hospital length of stay and composite neonatal morbidity and mortality, met the stopping criteria for statistical significance at the pre-planned interim analysis. We adopted the DSMB’s recommendation and stopped PRIME study enrollment to focus on analyzing and reporting the available data. In May 2024, deliveries of all PRIME study participants were complete, inclusive of the approximately 2,000 remaining participants who were enrolled but had not delivered before enrollment was stopped in December 2023 per DSMB recommendation. All mothers and babies within the study have left the hospital and data monitoring for the final PRIME dataset is in progress. Manuscripts reporting study results, including top-line and exploratory analyses, are being prepared for submission and peer review after final analysis expected in fall 2024.

We have built an advanced, proprietary, and scalable proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are highly accurate predictors of dynamic changes that occur during pregnancy. By incorporating our proprietary technology platform into our rigorous data-driven development process, we have created a differentiated approach for effectively addressing major milestones, conditions, and features of pregnancy. We believe our large and growing pregnancy dataset (clinical, demographic, proteomic) is a substantial asset for understanding pregnancy complications, health inequities, and the personal pregnancy journey. We envision that our comprehensive approach will enable us to fully characterize one of the most important periods in the lives of women and their babies, and will help to improve their well-being.

We are actively discovering and developing several additional biomarker tests to predict other specific major conditions of pregnancy, such as a pregnancy risk prediction panel test. We believe these tests have the potential to offer significant health benefits to women and their babies. Among other products, we are developing a test designed to provide a more accurate estimate of the delivery date for expectant mothers for the purposes of planning maternity leave, required support, travel arrangements, and related considerations.

Our operations are headquartered in Salt Lake City, Utah, including a CLIA-certified laboratory. Since our inception, we have devoted the majority of our efforts and resources to performing research and development, acquiring product rights, raising capital, establishing facilities, conducting clinical trials, and establishing commercial operations to develop and commercialize our testing and analytics products, primarily the PreTRM test. During this period, we have incurred annual net losses. We have largely funded our operations with proceeds from the sale and issuance of convertible preferred stock, debt financings, bank loans, and the sale and issuance of Class A common stock in our initial public offering, or IPO, which was completed in July 2021.

We have incurred significant operating losses since inception. Our net losses were $8.3 million and $10.5 million for the three months ended June 30, 2024 and 2023, respectively and $16.4 million and $21.1 million for the six months ended June 30, 2024 and 2023, respectively. We expect to incur significant additional operating losses and negative cash flows for the foreseeable future, principally as a result of our commercialization activities for the PreTRM test, and to support additional clinical studies, publications, and anticipated research and development of our other pipeline products and services.

We have taken steps to significantly reduce our annual operating expenses across all aspects of our business and we believe our cash runway is sufficient to enable us to operate into 2027 based on our existing operating plans. We will continue to evaluate the allocation of our resources as we focus our efforts to accelerate the market adoption of our PreTRM test and the development and launch of additional pipeline products and services. Our evidence portfolio continues to grow with the publication of the PREVENT-PTB study sub-analysis of the potential benefit of care coordination and low-dose aspirin paired with PreTRM test results.

We recently announced the publication of the positive results from the AVERT PRETERM TRIAL in Diagnostics, an international, peer-reviewed, open access journal on medical diagnosis. Diagnostics highlighted this study on the cover of the journal issue. Notable results indicated an 18% reduction in severe neonatal morbidity and mortality. Additionally, there was a 7-day reduction in the mean neonatal hospital length of stay among neonates with the longest stays. The trial also showed an increase in the average gestational age at birth before 32 weeks by 2.48 weeks. Furthermore, there was a

Table of Contents

28-day reduction in the neonatal length of hospital stay for babies born before 32 weeks’ gestation, significantly reducing the time spent in the hospital for those at risk of the earliest delivery. Significant reductions in neonatal morbidity and mortality were also reported, as well as hospital and NICU lengths of stay, in the entire intent-to-treat population. The test-and-treat strategy was linked to decreased odds of preterm birth and spontaneous preterm birth at various gestational ages.

Our real-world evidence implementation programs, targeting to expand PreTRM clinical utility data and replicate randomized controlled trial evidence in the real world, have been developed for study launches anticipated in the second half of 2024 and in 2025.

We recently completed validation of certain whole-blood collection and whole-blood compatible testing technologies, and have begun marketing and processing whole-blood specimens. This evolution to whole-blood collection will remove laborious specimen processing steps such as centrifugation and enable in-office physician or at-home consumer collection channels. We believe that whole-blood collection technologies, paired with ambient specimen shipment approaches, may enable greater market penetration and an optimal customer experience, while also potentially lowering costs.

We will continue to opportunistically pursue contracts with private and governmental payers and health systems with new positive data from the PREVENT-PTB study, the AVERT PRETERM TRIAL, and the PRIME study, along with real-world evidence studies and other data we plan to generate, and we believe these efforts may eventually result in material revenues. However, if we are unable to secure payer contracts and generate significant market adoption by providers resulting in significant revenues, or if we fail to develop and successfully market our additional tests that generate additional revenues, we may be required to delay, scale back or abandon some, or all, of our development programs and other operations. Until such time as we can generate significant revenue from the sales of our products, if ever, we may need to continue to finance our cash needs through equity offerings, debt financings or other capital sources, potentially including collaborations or other similar arrangements. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures or declaring dividends and may require the issuance of warrants. If we raise additional funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may have to significantly delay, reduce, or eliminate some or all of our product development or future commercialization efforts, or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. Our ability to access capital when needed is not assured and, if not achieved on a timely basis, will materially harm our business, financial condition, and results of operations.

Key Components of Our Results of Operations

Revenues

Substantially all of our revenue in the near term is expected to come from sales of the PreTRM test. We expect to derive future revenues from PreTRM and other pipeline tests. As we continue to engage with payers and health systems using our latest evidence, we aim to close additional contracts which are expected to eventually result in additional revenues when health care providers order the PreTRM test. We believe market adoption by both health care providers and payers could be aided by the publication of the PREVENT-PTB study sub-analysis, the recent publication of the AVERT PRETERM TRIAL results, the future publication of positive PRIME study data, and other evidence generated within the next three years. We believe market accessibility of the test could be improved by our recent developments in diversifying our specimen collection methods and enhanced awareness and engagement with patients. Revenue from our other pipeline products and services is expected to be dependent on our ability to successfully market them to patients, providers, payers, and, in most cases, a combination of the three.

Operating Expenses

Cost of Revenue

Cost of revenue reflects the aggregate costs incurred in delivering products to customers (e.g., proteomic testing results to clinicians) and includes expenses related to third-party specimen collection and shipping costs, as well as our lab personnel, materials and supplies, equipment, and infrastructure expenses associated with clinical testing, and allocated overhead including rent and equipment depreciation. Some of these components can vary significantly in cost and reliability of supply, and we periodically seek ways to make our supplier network more robust. For example, to address the

Table of Contents

risk posed by potential disruptions in specimen collection services described in the “Risk Factors” section of this report, we have contracted with alternative specimen collection providers beyond those that have traditionally supplied the majority of our needs, and have developed additional collection methods. We expect costs of revenue will generally move in line with the sales of our products.

Research and Development Expenses

Research and development expenses consist of costs incurred for our research activities and development of our product candidates. These expenses include:

•clinical and real-world studies;

•laboratory processes;

•research and bioinformatic activities;

•biobanking and publication efforts;

•personnel-related expenses, including salaries, payroll taxes, employee benefits, and stock-based compensation charges for employees engaged in these research and development activities;

•direct study expenses incurred under agreements with study sites or contract research organizations;

•consultants engaged in our research and development efforts;

•laboratory materials and supplies;

•facilities costs; and

•depreciation, amortization, and other direct and allocated expenses, including insurance, and other operating costs, incurred as a result of our research and development activities.

We expense all research and development costs, both internal and external, in the period in which they are incurred. We expect that our research and development expenses will increase slightly in 2024 compared to 2023 due to increased product development activities, offset by decreased clinical study costs following our ending enrollment in the PRIME study due to efficacy at the interim analysis at the end of 2023. Research and development costs may continue to increase in the medium to long-term as we support current and additional clinical studies, publications, and other product development activities.

Selling and Marketing Expenses

Selling and marketing expenses consist primarily of salaries, payroll taxes, employee benefits, and stock-based compensation charges for sales, marketing, and payer access personnel. Other significant costs include travel, consulting, public relations, and legal costs related to commercial efforts. We expect selling and marketing expenses will decrease in 2024 compared to 2023 as we recently took steps to further streamline our near-term commercial strategy to refocus on institutional sales as we generate additional clinical data. We expect selling and marketing expenses to accelerate as early as the second half of 2024 and further increase in the medium to long-term as we expand our investment in pursuit of PreTRM commercial opportunities, and as we increase our commercial investments in our product portfolio.

General and Administrative Expenses

General and administrative expenses consist primarily of salaries, payroll taxes, employee benefits, and stock-based compensation charges for personnel in executive, finance, information technology, human resources, and other administrative functions. Other significant costs include facilities, corporate and intellectual property legal fees, accounting, insurance, consulting, and other professional fees.

We expect general and administrative expenses in 2024 could remain consistent or decrease slightly compared to 2023, but such expenses could increase in the medium to long-term as needed to support future operations and anticipated revenue growth.

Interest Expense

Interest expense represents interest incurred on our finance leases.

Table of Contents

Other Income, Net

Other income, net consists of interest income and other investment income earned on our cash, cash equivalents, and marketable securities, and other gains and losses.

Results of Operations

The results of operations presented below should be reviewed in conjunction with the condensed financial statements and related notes included elsewhere in this report.

Comparison of the Three Months Ended June 30, 2024 and 2023

The following table summarizes our results of operations for the three months ended June 30, 2024 and 2023:


	Three Months Ended June 30,
	2024		2023		$ Change

	(in thousands)
	(unaudited)
Revenue	$	24	$	123	$	(99)
Operating expenses:
Cost of revenue	20		80		(60)
Research and development	4,406		3,688		718
Selling and marketing	1,099		2,872		(1,773)
General and administrative	3,752		4,943		(1,191)
Total operating expenses	9,277		11,583		(2,306)
Loss from operations	(9,253)		(11,460)		2,207
Interest expense	(8)		(14)		6
Other income, net	958		932		26
Net loss	$	(8,303)	$	(10,542)	$	2,239

Research and Development Expenses

The following table summarizes our research and development expenses for the three months ended June 30, 2024 and 2023:


	Three Months Ended June 30,
	2024		2023		$ Change

	(in thousands)
	(unaudited)
Research and development expenses:
Clinical studies	$	1,131	$	1,540	$	(409)
Research and bioinformatics	2,465		1,079		1,386
Laboratory operations	810		1,069		(259)
Total research and development expenses	$	4,406	$	3,688	$	718

The $0.7 million increase in total research and development expenses was due to a $1.4 million increase in research and bioinformatics costs, partially offset by a $0.4 million decrease in clinical study costs and a $0.3 million decrease in laboratory operations costs. The $1.4 million increase in research and bioinformatics costs was primarily due to a $0.7 million increase in consulting and outside processing expenses related to product development activities, a $0.5 million increase in stock-based compensation expense, and a $0.1 million increase in personnel costs due to increased average headcount. The $0.4 million decrease in clinical study costs was primarily due to a $0.3 million decrease in PRIME study costs resulting from stopping enrollment in December 2023 due to efficacy and a $0.2 million decrease in personnel costs due to decreased average headcount. The $0.3 million decrease in laboratory operations costs was primarily

Table of Contents

due to a $0.2 million decrease in personnel costs due to decreased average headcount and a $0.1 million decrease in lab supplies.

Selling and Marketing Expenses

The $1.8 million decrease was due primarily to decreases of $1.2 million in personnel-related costs driven by decreased average headcount, $0.2 million in stock-based compensation expense, $0.2 million in marketing programs and materials, and $0.1 million in travel expenses. These decreases are largely a result of steps we took to further streamline our near-term commercial strategy to refocus on institutional sales as we generate additional clinical data.

General and Administrative Expenses

The $1.2 million decrease was due primarily to decreases of $0.7 million related to one-time personnel costs, $0.3 million in personnel-related costs driven by decreased average headcount, $0.1 million of director and officer insurance costs, and $0.1 million in professional services fees. The decreases in personnel-related costs are largely a result of steps we took to streamline our general and administrative expenses to maintain the appropriate level of support for our current level of operations.

Comparison of the Six Months Ended June 30, 2024 and 2023

The following table summarizes our results of operations for the six months ended June 30, 2024 and 2023:


	Six Months Ended June 30,
	2024		2023		$ Change

	(in thousands)
	(unaudited)
Revenue	$	24	$	223	$	(199)
Operating expenses:
Cost of revenue	37		142		(105)
Research and development	8,089		7,791		298
Selling and marketing	2,326		5,690		(3,364)
General and administrative	7,922		9,389		(1,467)
Total operating expenses	18,374		23,012		(4,638)
Loss from operations	(18,350)		(22,789)		4,439
Interest expense	(17)		(30)		13
Other income, net	1,967		1,712		255
Net loss	$	(16,400)	$	(21,107)	$	4,707

Table of Contents

Research and Development Expenses

The following table summarizes our research and development expenses for the six months ended June 30, 2024 and 2023:


	Six Months Ended June 30,
	2024		2023		$ Change

	(in thousands)
	(unaudited)
Research and development expenses:
Clinical studies	$	2,145	$	3,370	$	(1,225)
Research and bioinformatics	4,271		2,175		2,096
Laboratory operations	1,673		2,246		(573)
Total research and development expenses	$	8,089	$	7,791	$	298

The $0.3 million increase in total research and development expenses was due to a $2.1 million increase in research and bioinformatics costs, partially offset by a $1.2 million decrease in clinical study costs and a $0.6 million decrease in laboratory operations costs. The $2.1 million increase in research and bioinformatics costs was primarily due to a $1.2 million increase in consulting and outside processing expenses related to product development activities, a $0.7 million increase in stock-based compensation expense, and a $0.2 million increase in personnel costs due to increased average headcount. The $1.2 million decrease in clinical study costs was primarily due to a $0.9 million decrease in PRIME study costs resulting from stopping enrollment in December 2023 due to efficacy and a $0.5 million decrease in personnel costs due to decreased average headcount, partially offset by a $0.1 million increase in consulting costs. The $0.6 million decrease in laboratory operations costs was primarily due to a $0.5 million decrease in personnel costs due to decreased average headcount and a $0.2 million decrease in lab supplies.

Selling and Marketing Expenses

The $3.4 million decrease was due primarily to decreases of $2.4 million in personnel-related costs driven by decreased average headcount, $0.4 million in travel expenses, $0.3 million in stock-based compensation expense, and $0.3 million in marketing programs and materials. These decreases are largely a result of steps we took to further streamline our near-term commercial strategy to refocus on institutional sales as we generate additional clinical data.

General and Administrative Expenses

The $1.5 million decrease was due primarily to decreases of $0.8 million in personnel-related costs driven by decreased average headcount, $0.6 million related to one-time personnel costs, $0.2 million of director and officer insurance costs, $0.2 million in professional services fees, and $0.2 million in other miscellaneous costs (such as facilities and equipment depreciation), partially offset by an increase of $0.6 million in stock-based compensation expense. The decreases in personnel-related and other miscellaneous costs are largely a result of steps we took to streamline our general and administrative expenses to maintain the appropriate level of support for our current level of operations.

Other Income, Net

The $0.3 million increase in other income, net was due to a $0.8 million increase related primarily to interest income on our marketable securities, partially offset by a $0.5 million decrease in investment income related primarily to our marketable securities.

Table of Contents

Liquidity and Capital Resources

Sources of Liquidity

Since inception, we have not generated a significant amount of commercial revenue from product sales or any other sources and have incurred significant operating losses and negative cash flows from operations. We anticipate that we will continue to incur net losses for the foreseeable future. We have financed our operations primarily through proceeds from the sale and issuance of convertible preferred stock and convertible notes, bank loans, and the sale and issuance of Class A common stock in our IPO, which was completed in July 2021. As of June 30, 2024, we had aggregate cash, cash equivalents, and available-for-sale securities of $80.9 million, and an accumulated deficit of $263.3 million.

Cash Flows

The following table summarizes our cash flows for the periods indicated:


	Six Months Ended June 30,
	2024		2023

	(in thousands)
	(unaudited)
Net cash provided by (used in):
Operating activities	$	(934)	$	(12,829)
Investing activities	(540)		15,228
Financing activities	2,258		8
Net increase in cash and cash equivalents	$	784	$	2,407

Operating Activities

The net cash used in operating activities during the six months ended June 30, 2024 was primarily due to a net loss of $16.4 million, partially offset by an increase in operating assets and liabilities of $11.7 million and non-cash charges of $3.8 million. The net cash used in operating activities during the six months ended June 30, 2023 was primarily due to a net loss of $21.1 million partially offset by non-cash charges of $3.1 million and an increase in operating assets and liabilities of $5.2 million.

Investing Activities

Net cash used in investing activities for the six months ended June 30, 2024 was primarily due to $26.6 million in purchases of marketable securities and $0.7 million in purchases of intangible assets, partially offset by $26.7 million in proceeds from maturities and sales of marketable securities. Net cash provided by investing activities for the six months ended June 30, 2023 was primarily due to $38.1 million in proceeds from maturities and sales of marketable securities, partially offset by $23.1 million in purchases of marketable securities.

Financing Activities

Net cash provided by financing activities for the six months ended June 30, 2024 was primarily due to $2.5 million in proceeds from employee equity transactions, partially offset by $0.2 million of finance lease principal payments. Net cash provided by financing activities for the six months ended June 30, 2023 was primarily due to $0.2 million in proceeds from employee equity transactions, partially offset by $0.2 million of finance lease principal payments.

Table of Contents

Future Funding Requirements

We expect to incur significant additional operating losses and negative cash flows for the foreseeable future. We expect our losses in the future to arise principally as a result of our commercialization activities for the PreTRM test and the development, commercialization, marketing, and distribution of our other pipeline products and services, especially the costs of evidence-generating initiatives. There can be no assurance that we will eventually achieve significant revenues or profitability, or if achieved, can sustain either on a continuing basis. If we are unable to achieve significant revenues or raise additional funding, when needed, we may not be able to continue the development or commercialization of our products and services and could be required to delay, scale back, or abandon some or all of our development programs and other operations. No assurance can be given that we will be successful in raising the required capital at reasonable cost and at the required times, or at all. Any additional equity financing may not be available on favorable terms, most likely will be dilutive to our current stockholders, and debt financing, if available, may involve restrictive covenants and dilutive financing instruments. Further, our operating plan may change, and we may need additional funds to meet operational needs and capital requirements for product development and commercialization sooner than planned. We currently have no credit facility or committed sources of capital. Our future funding requirements will depend on many factors, including the following:

•the timing, receipt, and amount of sales from the PreTRM test and other pipeline products and services;

•the cost and timing of establishing sales, marketing, and other commercialization capabilities in the United States and abroad;

•our ability to develop and commercialize other products and services;

•the terms and timing of any collaborative, licensing, and other arrangements that we may establish;

•the cost, timing, and outcomes of regulatory approvals;

•the scope, rate of progress, results, and cost of our clinical, scientific, and real-world studies, and other related activities;

•the cost of preparing, filing, prosecuting, defending, and enforcing any patent claims and other intellectual property rights;

•the extent to which we acquire or invest in businesses, products, services, or technologies, although we currently have no commitments or agreements relating to any of these types of transactions;

•partnerships and other strategic options for our PreTRM test and other product candidates; and

•other factors described in the “Risk Factors” section and elsewhere in this report.

We believe that our existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements for at least the next 12 months.

Contractual Obligations and Commitments

Our contractual obligations and commitments for the year ended December 31, 2023 are set forth in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on March 20, 2024. No material changes have occurred during the six months ended June 30, 2024.

Critical Accounting Policies and Estimates

A summary of our critical accounting policies and estimates is included in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the SEC on March 20, 2024. There have been no significant changes in the application of our critical accounting policies, significant judgments and use of estimates during the six months ended June 30, 2024.

Emerging Growth Company and Smaller Reporting Company Status

We are an emerging growth company, or EGC, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. We elected to use the extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that we (1) are no longer an EGC

Table of Contents

or (2) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies, reduce disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and are exempt from the requirements of holding a nonbinding advisory vote on executive compensation and any golden parachute payments not previously approved. As an EGC, we are also not required to have our internal control over financial reporting audited by our independent registered public accounting firm pursuant to Section 404 of the Sarbanes-Oxley Act. As a result, our financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates and we are not required to provide auditor attestation regarding requirements of Section 404(b) of Sarbanes-Oxley.

We will remain an EGC until the earliest to occur of: (1) the last day of the fiscal year in which we have at least $1.235 billion in annual revenue; (2) the last day of the fiscal year in which we are deemed to be a “large accelerated filer,” as defined in Rule 12b-2 under the Exchange Act, which would occur if the market value of our common stock held by non-affiliates exceeded $700.0 million as of the last business day of the second fiscal quarter of such year; (3) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period; and (4) December 31, 2026.

We are also a “smaller reporting company” as defined in the Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies until the fiscal year following the determination that the market value of our voting and non-voting common stock held by non-affiliates is more than $250 million measured on the last business day of our second fiscal quarter, or our annual revenues are less than $100 million during the most recently completed fiscal year and the market value of our voting and non-voting common stock held by non-affiliates is more than $700 million measured on the last business day of our second fiscal quarter.

Recent Accounting Pronouncements

A description of recent accounting pronouncements that may potentially impact our financial position, results of operations or cash flows is disclosed in Note 2—Significant Accounting Policies.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Interest Rate Risk

Our exposure to changes in interest rates relates primarily to interest earned and market value on our cash and cash equivalents and marketable securities.

Our cash and cash equivalents and marketable securities consist of cash held in banks, money market funds, commercial paper, U.S. government securities, U.S. federal agency securities and investment grade corporate securities. Our investment policy and strategy are focused on preservation of capital and supporting our liquidity requirements. Changes in U.S. interest rates affect the interest earned on our cash and cash equivalents and marketable securities, and the market value of those securities. A hypothetical 100 basis point increase in interest rates would have resulted in a decrease of $0.6 million in the market value of our available-for-sale debt securities as of June 30, 2024. Any realized gains or losses resulting from such interest rate changes would only occur if we sold the investments prior to maturity. We do not intend to sell investments while they are in an unrealized loss position and do not believe we will be required to sell the investments before recovery, which may be maturity.

Foreign Currency

We do not regularly incur expenses with vendors outside the United States or that are denominated in currencies other than the U.S. dollar. We may incur such expenses in the future at which point exchange rate fluctuations might adversely affect our expenses, results of operations, financial position and cash flows. To date, exchange rate fluctuations have not had a material effect on our results of operations.

Table of Contents

Effects of Inflation

We do not believe inflation has had a material effect on our results of operations during the periods presented. However, the current inflationary environment could affect us by increasing our costs of labor, laboratory supplies, and clinical trials and could adversely affect our business, results of operations, financial position and cash flows. In addition, increased inflation has had, and if it continues to increase, may have, an effect on interest rates and may adversely affect our borrowing rate and our ability to obtain any potential additional funding.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

We maintain “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Our management, with the participation of our Chief Executive Officer (our principal executive officer) and Chief Financial Officer (our principal financial officer and principal accounting officer), evaluated the effectiveness of our disclosure controls and procedures as of June 30, 2024. Based on the evaluation of our disclosure controls and procedures as of June 30, 2024, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting that occurred during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II — OTHER INFORMATION

Item 1. Legal Proceedings

We are not currently a party to any material litigation or other material legal proceedings. We may, from time to time, be involved in various legal proceedings arising from the normal course of business activities, and an unfavorable resolution of any of these matters could materially affect our future results of operations, cash flows, or financial position.

Item 1A. Risk Factors

Investing in our Class A common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below, the section of this Quarterly Report Form 10-Q entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our financial statements and related notes, before investing in our Class A common stock. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties that we are unaware of, or that we currently believe are not material, may also become important factors that affect us. If any of the following risks occur, our business, operating results and prospects could be materially harmed. In that event, the price of our Class A common stock could decline, and you could lose part or all of your investment.

Summary of Risk Factors

Our business is subject to numerous risks and uncertainties, including those highlighted in this section below, that represent challenges that we face in connection with the successful implementation of our strategy. The occurrence of one or more of the events or circumstances described in more detail in the risk factors below, alone or in combination with other events or circumstances, may have an adverse effect on our business, cash flows, financial condition, and results of operations. Such risks include, but are not limited to:

•We have incurred net losses since our inception and we anticipate that we will continue to incur losses for the foreseeable future, which could harm our future business prospects.

•Operating our business requires a significant amount of cash, and our ability to generate sufficient cash depends on many factors, some of which are beyond our control and if we cannot raise additional capital when needed, we may have to curtail or cease operations.

•Our quarterly and annual results may fluctuate from period to period, which could adversely impact the value of our Class A common stock.

•We have derived substantially all of our revenues to date from the PreTRM test, and if our efforts to further increase the use and adoption of the PreTRM test or to develop new products and services in the future do not succeed, our business will be harmed.

•In the near future, we expect to rely on sales to a limited number of direct customers for a significant portion of our revenue and cash flows related to the sale of the PreTRM test, making us subject to customer concentration risk.

•If we are unable to establish and maintain sales and marketing capabilities, we may not be successful in commercializing the PreTRM test.

•Competition in the life science industry, including companies engaged in molecular diagnostics and proteomics, is intense. If we are unable to compete successfully with respect to our current or future products or services, we may not be able to increase or sustain our revenues or achieve profitability.

•If our CLIA-certified laboratory facility becomes inoperable, we will be unable to perform our tests and our business will be harmed.

•Interim, top-line and preliminary data from our clinical trials that we announce or publish from time to time may change as additional data become available and are subject to confirmation, audit, and verification procedures that could result in material changes in the final data.

•Our business would be materially harmed if our proprietary biobank were to become contaminated, lost or destroyed.

•Some of our products and services rely heavily on access to internal and external databases, and loss of access to such databases could materially harm our business.

Table of Contents

•

SERA PROGNOSTICS, INC. [SERA] Filings
10-Q	[2024-08-07]
10-Q	[2024-05-08]
10-K	[2024-03-20]
10-Q	[2023-11-08]
10-Q	[2023-08-09]
10-Q	[2023-05-10]
10-K	[2023-03-22]
10-Q	[2022-11-09]
10-Q	[2022-08-10]
10-Q	[2022-05-10]
10-K	[2022-03-29]
10-Q	[2021-11-09]
10-Q	[2021-08-30]
S-1	[2021-06-11]